Sunovion reports positive results for Latuda in first placebo-controlled trial in MDD patients
This study demonstrated that Latuda (lurasidone HCl) significantly reduced depressive symptoms in adults with MDD with mixed features when compared to placebo. The study results were presented at
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.